Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.

Nature reviews. Clinical oncology - 1 Feb 2023

O'Leary Ben

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Circulating Tumor DNA
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 36424404
DOI: 10.1038/s41571-022-00712-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.PMID 36424404Read ↗

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.Semantic proximity Read ↗

ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.Semantic proximity Read ↗

Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancer.Semantic proximity Read ↗

Predicting treatment resistance and relapse through circulating DNASemantic proximity Read ↗

Assessing Endocrine Resistance: Monitoring Circulating ESR1 mutations in Irosustat-Treated ER positive Breast CancerSemantic proximity Read ↗

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity Read ↗

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.Semantic proximity Read ↗

ctDNA guides anti-EGFR rechallenge.Semantic proximity Read ↗

Anagrelide and the CALR mutation allele burden in essential thrombocythemia.Semantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring of <i>ESR1</i> and <i>PIK3CA</i> mutations from plasma cell-free DNASemantic proximity Read ↗

Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.